Aura Biosciences, Inc. (AURA) स्टॉक विश्लेषण

कंपनी का अवलोकन

Aura Biosciences, Inc. operates as a clinical-stage biotechnology firm dedicated to the development of precision therapies designed to treat solid tumors. The company utilizes a proprietary platform that enables the targeting of various solid tumors through the use of virus-like particles conjugated with drugs or loaded with nucleic acids. This enterprise functions within the broader Healthcare sector, specifically the Biotechnology industry, which focuses on the discovery and commercialization of advanced medical treatments. With a current market capitalization of $434.94M and an employee base of 113, the organization maintains a relatively compact scale typical for early-stage biotech entities. The valuation indicates that the market assigns a moderate worth to the company's intellectual property pipeline, while the absence of reported annual revenue figures suggests the business is currently in a phase where capital expenditure and research costs outweigh commercial income generation.

वित्तीय स्वास्थ्य

The reported Net Income for the trailing twelve months stands at -$106,191,000, while EBITDA is recorded at -$111,662,000, highlighting significant operational losses inherent to the clinical development stage. The gap between revenue and net income is not quantifiable in this context due to the lack of reported revenue data, yet the substantial negative net income reveals a cost structure dominated by research and development expenses rather than sales costs. Free Cash Flow is reported at -$48,088,376, indicating that the company is burning cash to fund its operations and platform development, which limits immediate financial flexibility but is often necessary for clinical-stage ventures. All three key margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, reflecting that the company has not yet generated revenue sufficient to calculate meaningful profitability percentages or that revenue is negligible relative to costs. On the balance sheet, the company holds $144.24M in cash against $17.38M in debt, resulting in a Debt to Equity ratio of 12.69, which implies a highly leveraged structure by traditional metrics though the cash position provides a substantial buffer. The Current Ratio is 8.15, suggesting an extremely strong short-term liquidity position where current assets significantly exceed current liabilities. Return on Equity is -73.5% and Return on Assets is -40.1%, metrics that reveal the company is currently destroying equity and assets on a per-dollar basis due to the absence of positive earnings.

मूल्यांकन आकलन

The P/E Ratio (TTM) is listed as N/A due to the negative earnings, while the Forward P/E is -3.34, a figure that implies the market is pricing in potential future earnings recovery or is utilizing a non-standard valuation model given the current loss. The Price to Book ratio is 3.15, indicating that the market values the company at more than three times its book value, which suggests a premium assigned to the company's intangible assets and future clinical potential. The Price to Sales ratio is N/A and the EV/EBITDA is -2.76, meaning traditional revenue-based or earnings-based valuation multiples are not applicable in their standard form for this specific period. The stock's 52-week trading range spans from a low of $4.34 to a high of $7.48, placing the current trading price within a specific volatility band defined by these historical extremes. The Beta value is 0.35, which signifies that the stock's price volatility is significantly lower than that of the broader market, indicating lower systematic risk relative to the overall equity index.

Growth & Income

Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, preventing a direct comparison of growth rates between earnings and revenue within the reported historical data. As a non-dividend payer, the company maintains a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning all available cash flow is theoretically reinvested into the business for research and development rather than distributed to shareholders. The absence of a dividend policy is standard for clinical-stage biotechnology firms that prioritize funding their proprietary platform and clinical trials over shareholder returns. Consequently, the overall growth and income profile is characterized by a reliance on future clinical milestones for value creation rather than current cash flow generation or dividend income.